Sep 29 2026 12:47 AM EST

Aehr Test Systems' Q4 Turnaround and Record Backlog Boost FY2027 Outlook

Aehr Test Systems (NASDAQ: AEHR) posted a profitable fourth quarter and announced a FY 2027 revenue outlook of $130‑$150 million, prompting the stock to rally more than 220% over the past six months as investors reassessed the company’s growth trajectory.

Quarter‑four revenue rose to $18.8 million, a 34% year‑over‑year increase, and GAAP net income flipped to $1.4 million ($0.04 per share) after a loss of $2.9 million a year earlier. Cash and cash equivalents jumped to $116.5 million, up from $37.1 million in February, while the effective backlog reached a record $100.6 million.

Quarter‑four results drive the re‑rating

The fourth‑quarter earnings beat the consensus forecast for earnings per share (‑$0.07) by delivering a small GAAP profit, and bookings surged to a record $60.7 million. Book‑to‑bill ratios in Q3 FY 2026 exceeded 3.5 ×, underscoring strong order flow despite a revenue dip earlier in the year.

Key customer wins underpin the backlog

From February through August 2026 the company announced multiple multi‑million‑dollar orders, including a $14 million AI‑processor FOX‑XP wafer‑level burn‑in contract (Feb 26), a $41 million hyperscale AI follow‑on order (Apr 16), and a series of silicon‑photonics follow‑on orders totalling over $30 million (June‑August). Additional silicon‑carbide wafer‑level orders exceeding $8 million reflect accelerating electric‑vehicle programs.

Macro and industry tailwinds

The semiconductor test‑equipment market is projected to expand >48% in 2025 to $11.2 billion, while AI‑driven capex is expected to reach $156 billion by 2027. The 2022 CHIPS Act and subsequent domestic incentives have accelerated fab expansions, increasing demand for wafer‑level burn‑in solutions. Growth in AI processors, silicon photonics for data‑center interconnects and SiC power devices aligns directly with Aehr’s diversified product portfolio.

Guidance and valuation implications

Management forecast FY 2027 revenue of $130‑$150 million, representing a 160‑200% year‑over‑year increase from FY 2026. Non‑GAAP net income is targeted at 18‑22% of revenue, a marked improvement from the 2026 loss. Analysts have upgraded the consensus to a “Moderate Buy,” with price targets averaging $132.50, implying upside of roughly 30% from current levels.

Risks and unanswered questions

The company remains exposed to geopolitical headwinds, notably U.S.–China export controls that can delay equipment orders and increase material costs for gallium and germanium. Customer concentration—particularly reliance on a few lead AI‑processor and silicon‑photonics accounts—means that any slowdown in those segments could compress the backlog. Execution risk also exists around scaling the newly acquired Incal Technology assets and meeting the aggressive FY 2027 revenue targets.